Keros Therapeutics, Inc. (KROS)
| Market Cap | 221.37M -60.3% |
| Revenue (ttm) | 33.18M -84.5% |
| Net Income | -85.15M |
| EPS | -2.66 |
| Shares Out | 19.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,094 |
| Open | 11.28 |
| Previous Close | 11.31 |
| Day's Range | 11.20 - 11.28 |
| 52-Week Range | 9.79 - 22.55 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 21.83 (+95.17%) |
| Earnings Date | May 14, 2026 |
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KROS stock is "Buy." The 12-month stock price target is $21.83, which is an increase of 95.17% from the latest price.
News
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
Reports Q1 revenue $367,000, consensus $1.69M. “Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities,” said Jasbir S. Seehra, P...
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ...
Keros Therapeutics Earnings release: Q1 2026
Keros Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Keros Therapeutics Quarterly report: Q1 2026
Keros Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Keros Therapeutics Proxy statement: Proxy filing
Keros Therapeutics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Keros Therapeutics Proxy statement: Proxy filing
Keros Therapeutics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Keros Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Significant progress included the transition of elritercept to Takeda, advancement of rinvatercept into DMD and ALS, and discontinuation of cibotercept. Rinvatercept showed promising Phase 1 results, and the ALS program was selected for a major consortium trial. Early pipeline expansion and a strong financial runway extend into 2028.
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
Keros Therapeutics (KROS) announced that it has entered into an agreement with the Massachusetts General Hospital, MGH, for the design of a Phase 2 clinical trial evaluating rinvatercept in patients…
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
Keros Therapeutics (KROS) announced that it presented additional data from its Phase 1 clinical trial of rinvatercept in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scient...
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
Wells Fargo lowered the firm’s price target on Keros Therapeutics (KROS) to $20 from $23 and keeps an Overweight rating on the shares. The firm notes no change to its…
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics Annual report: Q4 2025
Keros Therapeutics has published its Q4 2025 annual report on March 4, 2026.
Keros Therapeutics Earnings release: Q4 2025
Keros Therapeutics released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Keros Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Rinvatercept (KER-065) is advancing to phase II trials in DMD and ALS, showing strong preclinical and phase I data for muscle, bone, and fat improvements. The DMD trial will focus on late ambulatory and early non-ambulatory cohorts, with initial combination therapy alongside glucocorticoids. Significant Takeda partnership supports the pipeline.
Keros Therapeutics Appoints Charles Newton to its Board of Directors
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing rinvatercept for DMD and ALS, with a DMD trial starting this quarter and ALS regulatory engagement planned for the second half of the year. Elritercept, partnered with Takeda, is in phase III for MDS and MF, with commercialization targeted for late this decade. Cash reserves of $383M provide runway into 2028.
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics price target raised to $19 from $18 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Keros Therapeutics (KROS) to $19 from $18 and keeps a Neutral rating on the shares after adjusting projections following the…
Keros Therapeutics Announces Final Results of Tender Offer
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) ...
Keros Therapeutics Announces Preliminary Results of Tender Offer
LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Of...
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Keros Therapeutics (KROS) to $27 from $23 and keeps an Outperform rating on the shares following quarterly results and business…
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Keros Therapeutics (KROS) to $27 from $23 and keeps an Outperform rating on the shares following quarterly results. The firm…
Keros Therapeutics reports Q3 EPS (18c), consensus (92c)
Reports Q3 revenue $14.26M, consensus $4.22M. The net loss decrease of $45.7M was largely due to revenue recognized related to Keros’ license agreement with Takeda, partially offset by research and…